Emerald Advisers LLC Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Emerald Advisers LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 15.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,592 shares of the company’s stock after selling 281 shares during the quarter. Emerald Advisers LLC’s holdings in Eli Lilly and Company were worth $1,229,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Principal Financial Group Inc. increased its holdings in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Jim Saulnier & Associates LLC acquired a new position in shares of Eli Lilly and Company during the third quarter valued at about $210,000. Truepoint Inc. increased its holdings in Eli Lilly and Company by 99.1% in the 3rd quarter. Truepoint Inc. now owns 462 shares of the company’s stock worth $409,000 after buying an additional 230 shares during the period. Lane & Associates LLC increased its holdings in Eli Lilly and Company by 2.5% in the 3rd quarter. Lane & Associates LLC now owns 2,661 shares of the company’s stock worth $2,358,000 after buying an additional 66 shares during the period. Finally, WESPAC Advisors LLC increased its holdings in Eli Lilly and Company by 3.5% in the 3rd quarter. WESPAC Advisors LLC now owns 2,459 shares of the company’s stock worth $2,179,000 after buying an additional 84 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.4 %

Shares of NYSE:LLY opened at $839.44 on Monday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The firm has a market capitalization of $795.93 billion, a price-to-earnings ratio of 71.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The business’s 50 day moving average price is $835.99 and its 200-day moving average price is $838.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LLY shares. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Citigroup cut their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Finally, Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.